Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

Launched by BIOCAD · Jul 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medicine called BCD-261 to see if it can help people with moderate to severe Crohn’s disease, a condition that causes inflammation in the digestive tract. The study wants to find out how well the medicine works, how safe it is, how the body processes it, and how the immune system responds to it. Participants will be randomly assigned to receive either the new medicine or a placebo (a pill with no active drug), and neither the participants nor the researchers will know who gets which until the study is over.

Adults aged 18 to 75 with moderate to severe Crohn’s disease who have not responded well to standard treatments like steroids, immunosuppressants, or biologic medicines may be eligible. To join, participants must have had Crohn’s disease for at least three months with active symptoms confirmed by tests, and their disease should be moderate to severe based on specific clinical scores. During the study, participants will have their symptoms and health closely monitored to see if the new medicine helps reduce inflammation and improve their condition, while also watching for any side effects. This trial offers a chance for people struggling with Crohn’s disease despite current treatments to try a new option under careful medical supervision.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The diagnosis of Crohn's disease involving the terminal ileum or colon (types L1-L3 according to the Montreal classification), established ≥3 months prior to signing the informed consent form and confirmed by endoscopic findings.
• 2. Moderate to severe active Crohn's disease, manifested by the following signs:
• • (1) Crohn's Disease Activity Index (CDAI) ≥220 and ≤450 points.
• • (2) Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥6 points or ≥4 points for the disease form with isolated involvement of the ileum (according to central independent review).
• 3. Inadequate response to therapy according to the investigator's assessment, manifested by at least one of the following signs:
• • 1. Persistent symptoms of disease activity despite treatment with at least one course of glucocorticoids including prednisolone at a dose of ≥40 mg/day or equivalent or budesonide ≥9 mg/day or equivalent for at least 2 weeks with oral administration (at least 1 week with intravenous administration at a dose equivalent to oral prednisolone ≥40 mg/day).
• • 2. Steroid dependence manifested by an increase in disease activity after initial improvement, with a decrease in the dose of glucocorticoids below the dose equivalent to 10 mg of oral prednisolone per day, within 3 months from the beginning of treatment, or a relapse of the disease within 3 months after the end of glucocorticoid use.
• • 3. Persistent symptoms of disease activity despite treatment with at least one course of immunosuppressants (azathioprine at a dose of ≥2.0 mg/kg and/or 6-mercaptopurine at a dose of ≥1.0 mg/kg and/or methotrexate at a dose of ≥15.0 mg/week) for ≥12 weeks, or in response to another treatment regimen with these drugs according to a regional standard of care.
• • 4. Primary lack of response to therapy with TNFa inhibitors and/or anti-integrins, and/or IL-12/23 inhibitors, and/or targeted immunosuppressors (upadacitinib), defined as the persistence of symptoms of disease activity despite at least one course of induction of remission according to a treatment scheme approved by the regional standard.
• • 5. Loss of response to therapy with TNFa inhibitors and/or anti-integrins, and/or IL-12/23 inhibitors, and/or targeted immunosuppressors (upadacitinib), defined as the appearance of symptoms of disease activity after initial improvement as a result of treatment with at least one course of induction of remission and at least one course of maintenance of remission according to a treatment scheme approved by the regional standard.
• • 6. A history of intolerance to glucocorticoid therapy and/or immunosuppressors (azathioprine, 6-mercaptopurine, methotrexate) and/or biologic therapies (TNFα inhibitors, anti-integrins, IL-12/23 inhibitors) and/or targeted immunosuppressors (upadacitinib), as determined by the treating physician.
• • 4. Maintaining a stable dose of concomitant medications for ≥2 weeks prior to signing the ICF and in the screening period for glucocorticoids and for ≥4 weeks prior to signing the
• • ICF and in the screening period for immunosuppressants (azathioprine, 6-mercaptopurine, methotrexate).
• Exclusion Criteria:
• • 1. A history of or current at the time of signing the ICF ulcerative colitis, unspecified colitis, ischemic colitis, radiation colitis, microscopic colitis, complicated form of diverticular disease.
• • 2. A history of primary sclerosing cholangitis.
• • 3. Presence of active intra-abdominal or perianal abscess at the time of signing the ICF.
• • 4. Presence of an endoscopically obstructed stricture/stenosis of the intestine at the time of signing the ICF.
• • 5. A history of toxic megacolon, intestinal obstruction, intestinal perforation (except for those caused by injury or appendicitis).
• • 6. A history of dysplasia in any part of the gastrointestinal tract at the time of signing the ICF.
• • 7. Previous resections of the small intestine with a total length of resected segments \>100 cm and/or resection of \>2 segments of the large intestine (ascending colon (including the cecum), transverse colon, descending colon (including the sigmoid colon), rectum)3.
• • 8. Presence of intestinal stoma or artificial rectum or the need for them.
• • 9. Failure of ≥3 classes of biologics/targeted immunosuppressors (according to INN) with different mechanisms of action (TNFa inhibitors, anti-integrins, IL-12/23 inhibitors, upadacitinib) or ≥4 biologics/targeted immunosuppressants (according to INN), regardless of the mechanism of actio
• * Use of any of the indicated therapies within the specified time frame or need for therapy with these drugs during the study period:
• • 1. Use of TNFa inhibitors within 8 weeks prior to signing the ICF or during the screening period.
• • 2. Use of anti-integrins or IL-12/23 inhibitors within 12 weeks before signing the ICF or during the screening period.
• • 3. Use of Janus kinase inhibitors (upadacitinib) within 2 weeks prior to signing the ICF or during the screening period.
• • 4. Use of oral glucocorticoids at a dose equivalent to prednisone \>20 mg/day or budesonide \>9 mg/day or rectal administration of glucocorticoids at any dose within 2 weeks prior to signing the ICF or during the screening period or parenteral administration of glucocorticoids at any dose within 4 weeks prior to signing the ICF or during the screening period.
• • 5. Use of immunosuppressants not included in the approved therapy (tacrolimus, cyclosporine, mycophenolate mofetil, rapamycin, leflunomide, penicillamine, etc.) within 4 weeks before signing the ICF or during the screening period.
• • 6. Long-term regular use of non-steroidal anti-inflammatory drugs (≥3 times a week for ≥6 weeks) for 2 weeks prior to signing the ICF.
• • 7. Use of any other investigational drugs in other clinical trials at the time of signing the ICF or less than 8 weeks or 5 half-lives (whichever is longer) before the date of signing the ICF or during screening.